A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

NCT01208181 PHASE3 COMPLETED Results posted

This is a 2-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study.

Details

Lead sponsor	Organon and Co
Phase	PHASE3
Status	COMPLETED
Enrolment	1404
Start date	Mon Sep 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Arthritis, Rheumatoid

Interventions

• Etoricoxib 60 mg
• Etoricoxib 90 mg
• Placebo to Etoricoxib 60 mg
• Placebo to Etoricoxib 90 mg